Price per pack (10 vials). Discount applies to this compound only – no mix and match.
| 10mg | ||
|---|---|---|
| Quantity | Price per Pack | Savings |
| 1 pack | $200 per pack | |
| 2 packs | $170 per pack | 15% off |
| 3 packs | $144 per pack | 28% off |
| 5 packs | $130 per pack | 35% off |
| 10 packs | $117 per pack | 42% off |
| 25 packs | $105 per pack | 48% off |
SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide that mimics the N-terminal domain of SNAP-25 (synaptosomal-associated protein 25kDa), a core component of the neuronal SNARE complex. SNAP-25 was characterized extensively in the 1990s as one of three proteins — alongside syntaxin-1 and synaptobrevin/VAMP — required for synaptic vesicle docking and calcium-triggered neurotransmitter exocytosis. SNAP-8 was developed as a longer, higher-affinity variant of Acetyl Hexapeptide-3 (argireline): the addition of two N-terminal amino acids to the hexapeptide sequence increases competitive binding affinity for the SNARE complex assembly site. By competing with endogenous SNAP-25 for incorporation into the SNARE complex, SNAP-8 attenuates vesicle docking efficiency and reduces acetylcholine release at neuromuscular junctions in in vitro assay systems. Research with this compound operates primarily within cosmeceutical biology and neuromuscular junction signaling.
The SNARE complex (formed by SNAP-25, syntaxin-1, and synaptobrevin) operates as the core fusion machinery for synaptic vesicle exocytosis. SNAP-25 contributes two alpha-helical domains (Sn1 and Sn2) to the four-helix SNARE bundle. SNAP-8’s sequence mimics the Sn1 domain’s N-terminal region, allowing it to enter SNARE assembly in partial competition with the endogenous protein. This partial inhibition of vesicle docking reduces the quantum of acetylcholine released per nerve impulse at the neuromuscular junction — a mechanism studied in the context of expression wrinkle formation, where repetitive muscle contraction is driven by acetylcholine signaling. Unlike botulinum toxin, which irreversibly cleaves SNAP-25, SNAP-8’s inhibition is competitive and reversible.
| Mechanism | Effect |
|---|---|
| Competitive SNAP-25 displacement from SNARE complex | Reduced vesicle docking efficiency; attenuated acetylcholine release per stimulus |
| Sn1 domain mimicry (N-terminal SNAP-25 sequence) | Partial incorporation into four-helix SNARE bundle; reversible competitive inhibition |
| Neuromuscular junction acetylcholine output reduction | Reduced motor neuron-to-muscle signal transduction in cell-based models |
| Higher SNARE affinity than Acetyl Hexapeptide-3 (argireline) | Greater competitive displacement at equivalent concentrations in binding assays |
| No proteolytic SNAP-25 cleavage (contrast: botulinum toxin) | Fully reversible mechanism; SNARE complex function restored after compound removal |
SNAP-8 is used in studies examining:
| Format | Lyophilized powder |
| Purity | ≥99% |
| Aliases | Acetyl Octapeptide-3, Leuphasyl, Acetyl-EEMQRRAD-NH2 |
| Available sizes | 10mg |
| Storage | 2–8°C unopened; stable 12+ months |
| Use | Research purposes only — not for human use |
SNAP-8 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:
Total mg ÷ Volume added (mL) = Concentration (mg/mL)
Example: 10mg vial + 2mL BAC water = 5mg/mL solution
Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.
Published in vitro and cosmeceutical research provides the following reference frameworks — not instructions for use:
SNAP-8 is commonly paired in research settings with:
Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.



